|Chemical and physical data|
|Molar mass||345.385 g/mol g·mol−1|
|3D model (JSmol)|
Tedalinab (GRC-10693) is a drug developed by Glenmark Pharmaceuticals for the treatment of osteoarthritis and neuropathic pain, which acts as a potent and selective cannabinoid CB2 receptor agonist. It has a very high selectivity of 4700x for CB2 over the related CB1 receptor, has good oral bioavailability and has shown promising safety results and effective analgesic and antiinflammatory actions in early clinical trials. A large number of related compounds are known, most of which also show high CB2 selectivity.
- Glenmark’s Molecule for Neuropathic Pain, Osteoarthritis – GRC 10693, Successfully Completes Phase I Trials. April 13, 2009.
- Glenmark Pharmaceuticals. NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION, Filed June 1st, 2006. WO 2006/129178.